Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 1, 1997, Pages 43-47

  Koehler, Maria ^a   George, Kirsten St ^b   Ehrlich, G D Garth D ^b   Mirro, Joseph ^a   Neudorf, Steven M ^a   Rinaldo, Charles ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antigenemia; Bone marrow transplantation; Cytomegalovirus infection; Diagnosis; Polymerase chain reaction; Prevention

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN DETECTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030981399     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199701000-00006     Document Type: Article

References (30)

1. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19: 287-98.
2. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8.
3. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?. Blood 1994; 83: 2392-8.
4. Ljungman P, De Bock R, Cordonnier C, et al. Practices for cytomegalovirus diagnosis, prophylaxis, and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Disease of the EBMT. Bone Marrow Transplant 1993; 12: 399-403.
5. Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-64.
6. Revello MG, Percivalle E, Zavattoni M, et al. Detection of human cytomegalovirus immediate-early antigen in leukocytes as a marker of viremia in immunocompromised patients. J Med Virol 1989; 29: 88-93.
7. Singhal S, Mehta J, Powles R. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. Blood 1994; 84: 2055-6.
8. Gerna G, Revello MG, Percivalle E, et al. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232-7.
9. St. George K, Rinaldo CR Jr. Effects of enhancing agents on detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1994; 32: 2024-7.
10. Grossi P, Minoli L, Percivalle E, et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995; 59: 847-51.
11. Bacigalupo A, Tedone E, Isaza A, et al. CMV antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-61.
12. Koehler M, St. George K, Rinaldo C Jr. The evaluation of results of CMV antigenaemia assays in bone marrow transplant recipients. Br J Haematol 1995; 89: 427-8.
13. Randhawa PS, Jaffe R, Faruki H, et al. Detection of cytomegalovirus in formalin-fixed paraffin-embedded donor, native and allograft liver tissue using a multiplex polymerase chain reaction-liquid hybridization assay. Mod Pathol 1994; 7: 125-8.
14. Nolte FS, Emmens RK, Thurmond C, et al. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995; 33: 1263-6.
15. Imbert-Marcille BM, Milpied N, Coste-Burel M, et al. Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. Bone Marrow Transplant 1995; 15: 611-7.
16. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplant. Blood 1995; 87: 2815-20.
17. Finn WF. CMV-enriched immune globulin produces consistent reliable results in renal transplant patients. Transplantation 1993; 56: 491.
18. Gleaves CA, Smith TF, Shuster EA, et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917-9.
19. St. George K, Rinaldo CRJ. Comparison of monoclonal antibodies for immunostaining in the cytomegalovirus shell vial assay on 4,388 specimens. J Med Virol 1995; 47: 269-71.
20. Roberts WD, Weinberg KI, Kohn DB, et al. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection. Am J Pediatr Hematol Oncol 1993; 15: 320-3.
21. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-8.
22. Bacigalupo A, Van Lint MT, Tedone E, et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-8.
23. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 777-81.
24. Iberer F, Tscheliessnigg KH, Halwachs G, et al. CMV after heart transplantation: definitions for the guidance of antiviral therapy [Abstract 38]. 5th International CMV Conference, Stockholm, Sweden, May 1995.
25. Bowden RA, Fisher LD, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991; 164: 483-7.
26. Messori A, Rampazzo R, Scroccaro G, et al. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994; 13: 163-7.
27. Winston DJ, Ho WG, Bartoni K, et al. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 283-8.
28. Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12: 273-82.
29. Gross TG, Wagner JE, Filipovich AH, et al. Removal of cells infected with human herpesviruses by counterflow elutriation. Am Soc Blood Marrow Transplant 1995; 67.
30. Boeckh M, Gooley T, Myerson D, et al. Early ganciclovir treatment of CMV antigenemia versus ganciclovir at engraftment for prevention of CMV disease after allogeneic marrow transplant [Abstract 37]. 5th International CMV Conference, Stockholm, Sweden, May 1995.